▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

What Was Behind Ariad's 40% Drop?

By Max Macaluso, Dave Williamson, and Alison Southwick – Oct 18, 2013 at 7:07PM

Ariad Pharmaceuticals has already dropped significantly this week --- what was behind today's move?

This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and discusses the implementation of the Affordable Care Act, also known as Obamacare.

In this segment, analysts David Williamson and Max Macaluso discuss the reasons behind today's 40% drop in shares of Ariad Pharmaceuticals (NASDAQ: ARIA), an oncology-focused biotech company that is facing major headwinds regarding its chronic myeloid leukemia drug Iclusig.

Game-changing biotechs

Alison Southwick has no position in any stocks mentioned. David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services